Cancer Innovation最新文献

{"title":"A bibliometric analysis of worldwide cancer research using machine learning methods","authors":"Lianghong Lin,&nbsp;Likeng Liang,&nbsp;Maojie Wang,&nbsp;Runyue Huang,&nbsp;Mengchun Gong,&nbsp;Guangjun Song,&nbsp;Tianyong Hao","doi":"10.1002/cai2.68","DOIUrl":"https://doi.org/10.1002/cai2.68","url":null,"abstract":"<p>With the progress and development of computer technology, applying machine learning methods to cancer research has become an important research field. To analyze the most recent research status and trends, main research topics, topic evolutions, research collaborations, and potential directions of this research field, this study conducts a bibliometric analysis on 6206 research articles worldwide collected from PubMed between 2011 and 2021 concerning cancer research using machine learning methods. Python is used as a tool for bibliometric analysis, Gephi is used for social network analysis, and the Latent Dirichlet Allocation model is used for topic modeling. The trend analysis of articles not only reflects the innovative research at the intersection of machine learning and cancer but also demonstrates its vigorous development and increasing impacts. In terms of journals, <i>Nature Communications</i> is the most influential journal and <i>Scientific Reports</i> is the most prolific one. The United States and Harvard University have contributed the most to cancer research using machine learning methods. As for the research topic, “Support Vector Machine,” “classification,” and “deep learning” have been the core focuses of the research field. Findings are helpful for scholars and related practitioners to better understand the development status and trends of cancer research using machine learning methods, as well as to have a deeper understanding of research hotspots.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 3","pages":"219-232"},"PeriodicalIF":0.0,"publicationDate":"2023-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.68","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50128616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the treatment of solid tumors in children and adolescents","authors":"Jing Tian,&nbsp;Jiayu Wang,&nbsp;Sidan Li","doi":"10.1002/cai2.66","DOIUrl":"https://doi.org/10.1002/cai2.66","url":null,"abstract":"<p>Tumor is one of the leading causes of death in children (0 to 14-year-old) and adolescents (15 to 19-year-old) worldwide. Unlike adult tumors, childhood and adolescent tumors are unique in their type, molecular characteristics, and pathogenesis, and their treatment involves many challenges. In recent years, with the development of a large number of clinical studies, the survival rate of children and adolescents with tumors has improved significantly. The extensive research and application of optimized treatment regimens and new targeted drugs have led to new hope for the treatment of childhood and adolescent tumors. This article reviews the clinical and basic research and treatment of childhood and adolescent tumors and provides new ideas for the future development of precise treatment of childhood and adolescent tumors.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 2","pages":"131-139"},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.66","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50138514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chaotic fractals: Why chaos is the dynamic of carcinogenesis","authors":"Mesut Tez","doi":"10.1002/cai2.63","DOIUrl":"https://doi.org/10.1002/cai2.63","url":null,"abstract":"<p>We can see the fractals in our environment every day (trees, snowflakes, broccoli, etc.). Even the shapes of the DNA helix and anatomical structures are fractal, for example, the branching of blood vessels, bronchi, and cell membranes [<span>1</span>]. Unlike euclidean geometry, fractal geometry reveals how an object with irregularities in many dimensions can be identified by examining how the number of features in one dimension relates to the number of similarly shaped features in other dimensions [<span>2</span>]. Mandelbrot used fractal geometry to describe such irregular shapes and demonstrated that this geometry was an appropriate mathematical language for describing chaotic systems [<span>1</span>]. In fractal geometry, the fractal dimension (FD) is a statistical quantity that gives an indication of how completely a fractal appears to fill space, as one zooms down to finer and finer scales. The FD provides a measure of the complexity of a structure. Increased FD is an indicator of chaos [<span>3</span>].</p><p>A complex adaptive system (CAS) is a type of system that is composed of many interacting components, called agents, which can adapt and change their behavior based on their interactions with the environment and with other agents. CAS are characterized by their ability to self-organize and evolve over time, often resulting in emergent properties and behaviors that cannot be predicted from the properties of the individual agents alone. Examples of CAS include ecosystems, economies, social networks, and the human brain. It is also worth noting that a CAS can have both chaotic and regular behavior depending on the circumstances and the complexity of the system. Stem cells can also be considered CAS because they possess many of the characteristics that define CAS. Stem cells have the ability to self-renew, differentiate into multiple cell types, and respond to signals from their environment [<span>4</span>]. Some studies suggest an important role of the feedback loop between cancer cells and the microenvironment. Also, putting cells into an “inappropriate” microenvironmental context can otherwise trigger pathological issues, and even neoplastic transformation [<span>5</span>]. Cancer has previously been demonstrated to be a chaotic behavior of the stem cell [<span>6</span>].</p><p>The FD of chromatin has been demonstrated to increase during carcinogenesis and tumor growth in diffuse large B-cell lymphoma, chronic lymphocytic leukemia, oropharyngeal carcinoma, and hepatocarcinoma compared to equivalent normal tissue. A research study of over 3000 cancer specimens revealed the prevalence of fractal chromatin structure in neoplasias, as well as the importance of this arrangement in the creation of chromosomal abnormalities [<span>7</span>]. Fractal analysis of the cell surface is a rather sensitive method that has been recently introduced to characterize cell progression toward cancer. Analysis of FD of cell surface imaged with atomic forc","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 3","pages":"165-166"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.63","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50148152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resveratrol activation of SIRT1/MFN2 can improve mitochondria function, alleviating doxorubicin-induced myocardial injury","authors":"Qingling Zhang,&nbsp;Yunpeng Zhang,&nbsp;Bingxin Xie,&nbsp;Daiqi Liu,&nbsp;Yueying Wang,&nbsp;Zandong Zhou,&nbsp;Yue Zhang,&nbsp;Emma King,&nbsp;Gary Tse,&nbsp;Tong Liu","doi":"10.1002/cai2.64","DOIUrl":"https://doi.org/10.1002/cai2.64","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Doxorubicin is a widely used cytotoxic chemotherapy agent for treating different malignancies. However, its use is associated with dose-dependent cardiotoxicity, causing irreversible myocardial damage and significantly reducing the patient's quality of life and survival. In this study, an animal model of doxorubicin-induced cardiomyopathy was used to investigate the pathogenesis of doxorubicin-induced myocardial injury. This study also investigated a possible treatment strategy for alleviating myocardial injury through resveratrol therapy in vitro.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adult male C57BL/6J mice were randomly divided into a control group and a doxorubicin group. Body weight, echocardiography, surface electrocardiogram, and myocardial histomorphology were measured. The mechanisms of doxorubicin cardiotoxicity in H9c2 cell lines were explored by comparing three groups (phosphate-buffered saline, doxorubicin, and doxorubicin with resveratrol).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to the control group, the doxorubicin group showed a lower body weight and higher systolic arterial pressure, associated with reduced left ventricular ejection fraction and left ventricular fractional shortening, prolonged PR interval, and QT interval. These abnormalities were associated with vacuolation and increased disorder in the mitochondria of cardiomyocytes, increased protein expression levels of α-smooth muscle actin and caspase 3, and reduced protein expression levels of Mitofusin2 (MFN2) and Sirtuin1 (SIRT1). Compared to the doxorubicin group, doxorubicin + resveratrol treatment reduced caspase 3 and manganese superoxide dismutase, and increased MFN2 and SIRT1 expression levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Doxorubicin toxicity leads to abnormal mitochondrial morphology and dysfunction in cardiomyocytes and induces apoptosis by interfering with mitochondrial fusion. Resveratrol ameliorates doxorubicin-induced cardiotoxicity by activating SIRT1/MFN2 to improve mitochondria function.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 4","pages":"253-264"},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.64","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50155856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large cell neuroendocrine carcinoma transformation: A novel acquired drug resistance mechanism in colorectal adenocarcinoma","authors":"Feng Du,&nbsp;Ying Han,&nbsp;Xiao Hu,&nbsp;Yanjie Xiao,&nbsp;Youwu Shi,&nbsp;Jing Sun,&nbsp;Zhiwei Sun,&nbsp;Ying Yang,&nbsp;Jing Yu,&nbsp;Xiaodong Zhang,&nbsp;Jun Jia","doi":"10.1002/cai2.57","DOIUrl":"https://doi.org/10.1002/cai2.57","url":null,"abstract":"<p>Acquired resistance is a major problem limiting the clinical efficacy of treatments for metastatic colorectal cancer (mCRC). Histological transformation is an important mechanism underlying the acquired resistance of non-small cell lung cancer and prostate cancer to targeted therapy. However, no report has examined the role of histological transformation in mCRC. Here, we report the first case of histologically transformed large cell neuroendocrine carcinoma from primary colon adenocarcinoma during antiangiogenesis and anti-PD-1 combination therapy. The histologic conversion was confirmed by the observation that the transformed large cell neuroendocrine carcinoma lesion retained the original mutational signature found in the primary tumor. Sequential tumor biopsy and dynamic changes in tumor markers demonstrated the transformed process. The histological transformation not only resulted in discordant responses to the same treatment but also significantly shortened overall survival. This case calls for more attention to histological transformation in mCRC. Tumor rebiopsy upon disease progression and monitoring dynamic changes in tumor markers would help to identify such cases.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 2","pages":"159-164"},"PeriodicalIF":0.0,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.57","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flexible bioelectronic innovation for personalized health management","authors":"Maowen Xie,&nbsp;Guang Yao,&nbsp;Yuan Lin","doi":"10.1002/cai2.61","DOIUrl":"https://doi.org/10.1002/cai2.61","url":null,"abstract":"<p>With the vigorous development of intelligent medical care and interdisciplinary science, innovative flexible bioelectronics (FBEs) are emerging in health monitoring, disease diagnosis and treatment, and even cancer therapy. This work comments on the recent progress of FBEs in personalized health management, emphasizing its innovative role in cancer therapy. Future perspectives on the challenges and opportunities for the next-generation innovative FBEs are also proposed.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 3","pages":"167-171"},"PeriodicalIF":0.0,"publicationDate":"2023-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.61","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50129938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and prospects of drug clinical research in colorectal cancer in 2022","authors":"Dan Su,&nbsp;Chao Liu,&nbsp;Jie Cui,&nbsp;Jiebing Tang,&nbsp;Yuli Ruan,&nbsp;Yanqiao Zhang","doi":"10.1002/cai2.62","DOIUrl":"https://doi.org/10.1002/cai2.62","url":null,"abstract":"<p>Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death worldwide. Clinical research results have provided more treatment opportunities for CRC patients, showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease. In this review, we have summarized recent advances in drug clinical research for CRC in 2022, including chemotherapy, targeted therapy, and immunotherapy, to find opportunities for substantial improvements in drug discovery and clinical development methods.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 2","pages":"99-113"},"PeriodicalIF":0.0,"publicationDate":"2023-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.62","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50122160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma","authors":"Yuekun Wang,&nbsp;Shenglan Li,&nbsp;Yichen Peng,&nbsp;Wenbin Ma,&nbsp;Yu Wang,&nbsp;Wenbin Li","doi":"10.1002/cai2.59","DOIUrl":"https://doi.org/10.1002/cai2.59","url":null,"abstract":"<p>Glioblastoma (GBM) is the most common primary central nervous system tumor, whose prognosis remains poor under the sequential standard of care, such as neurosurgery followed by concurrent temozolomide radiochemotherapy and adjuvant temozolomide chemotherapy in the presence or absence of tumor treating fields. Accordingly, the advent of molecular targeted therapy and immunotherapy has opened a new era of tumor management. A diverse range of targeted drugs have been tested in patients with GBM in phase III clinical trials. However, these drugs are ineffective for all patients, as evidenced by the fact that only a minority of patients in these trials showed prolonged survival. Furthermore, there are several published phase III clinical trials that involve immune checkpoint inhibitors, peptide vaccines, dendritic cell vaccines, and virotherapy. Accordingly, this review comprehensively overviews existing studies of targeted drugs and immunotherapy for glioma and discusses the challenge and perspective of targeted drugs and immunotherapy for glioma to clarify future directions.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 2","pages":"114-130"},"PeriodicalIF":0.0,"publicationDate":"2023-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.59","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50122161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of YES1 signaling in tumor therapy resistance","authors":"Hai Zhou,&nbsp;Dantong Sun,&nbsp;Junyan Tao,&nbsp;Mingjin Xu,&nbsp;Xiaochun Zhang,&nbsp;Helei Hou","doi":"10.1002/cai2.51","DOIUrl":"https://doi.org/10.1002/cai2.51","url":null,"abstract":"<p>YES proto-oncogene 1 (YES1) is an SRC family kinase (SFK) that plays a key role in cancer cell proliferation, adhesion, invasion, survival, and angiogenesis during tumorigenesis and tumor development. Reports suggest that <i>YES1</i> amplification is associated with resistance to chemotherapeutic drugs and tyrosine kinase inhibitors (TKIs) in human malignancies. However, the mechanisms of drug resistance have not been fully elucidated. In this article, we review the literature on YES1 and discuss the implications of YES1 signaling for targeted therapy and chemotherapy resistance in malignancies. Moreover, recent advances in targeted therapy for <i>YES1</i>-amplified malignancies are summarized. Finally, we conclude that targeting YES1 may reverse drug resistance and serve as a valuable tumor treatment strategy.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 3","pages":"210-218"},"PeriodicalIF":0.0,"publicationDate":"2023-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.51","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50125018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The landscape of investigator-initiated oncology trials conducted in mainland China during the past decade (2010–2019)","authors":"Ye Cao,&nbsp;Lin-Miao Ye,&nbsp;Zhong Fan,&nbsp;Wei Yang,&nbsp;Li-Ying Chen,&nbsp;Yun Mei,&nbsp;De-Ying He,&nbsp;Wen-Jin Mo","doi":"10.1002/cai2.58","DOIUrl":"https://doi.org/10.1002/cai2.58","url":null,"abstract":"<p>The number of clinical trials conducted in mainland China, including investigator-initiated trials (IITs), has increased rapidly in recent years. However, there are few data on the characteristics of cancer-related IITs. We performed a comprehensive analysis of the landscape of cancer-related IITs in mainland China in the past decade. All cancer-related IITs registered on two clinical trial registries in the United States (www.clinicaltrials.gov, CT.gov) and mainland China (www.chictr.org.cn, ChiCTR) from 2010 to 2019 were identified. IITs were reviewed manually to validate classification, subcategorized by cancer type, and stratified by design characteristics to facilitate comparison across cancer types and with other specialties. A total of 8199 cancer-related IITs were identified. The number of trials registered annually increased over time, especially in the last 5 years. Although interventional studies were predominant, randomized double-blind studies accounted for only 8% of IITs. In the past decade, the trend for interventional studies conducted with different drugs increased year on year, although the increase in hormonal therapy IITs was not significant. Additionally, cancer-related IITs were unevenly geographically distributed, with half concentrated in the economically developed cities Shanghai, Beijing, and Guangdong. We also found an increase in registration before participant enrollment (64.9% for trials in conducted in 2015–2019 vs. 40.2% in 2010–2014, <i>p</i> &lt; 0.001) and data monitoring committee use (44.5% vs. 40.0%, <i>p</i> = 0.001) and a decrease in randomization (51.5% vs. 62.7%, <i>p</i> &lt; 0.001) and funding (36.4% vs. 56.3%, <i>p</i> &lt; 0.001) between these periods. We also observed changes in intervention type (decrease in cytotoxic drug therapy [34.8% vs. 48.9%, <i>p</i> &lt; 0.001]; increase in targeted therapy [17.8% vs. 14.2%, <i>p</i> = 0.004], immune checkpoint inhibitor therapy [6.6% vs. 0.0%, <i>p</i> &lt; 0.001], and immune cell therapy [9.6% vs. 4.5%, <i>p</i> &lt; 0.001]). Details of cancer-related IITs conducted during the past decade illustrate the merits of oncology research in mainland China. Although the increased quantity of IITs is encouraging, limitations remain regarding the quality of clinical trials, regional imbalances, and funding allocation.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"2 1","pages":"79-90"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.58","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50116543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}